Bank Hapoalim BM’s AstraZeneca AZN Stock Holding History

Bank Hapoalim BM’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-14,658	Closed	-$993K	–	203
2017 Q3	$993K	Sell	14,658 -6,432	-30%	-$406K	0.23%	84
2017 Q2	$1.44M	Sell	21,090 -350	-2%	-$22.9K	0.34%	63
2017 Q1	$1.33M	Buy	+21,440	New	+$1.25M	0.31%	69
2016 Q4	–	Sell	-8,143	Closed	-$535K	–	183
2016 Q3	$535K	Buy	+8,143	New	+$532K	0.13%	122

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank Hapoalim BM's AZN Position: Q4 2017 in Review

Bank Hapoalim BM sold out of AstraZeneca (AZN) in Q4 2017, closing a stake of 14,658 shares — an estimated $993K sold.

Bank Hapoalim BM first reported a position in AZN in Q3 2016 and held it in 4 quarters. The position peaked at $1.44M in Q2 2017. 503 funds tracked by Wall St. Rank hold AZN as of Q4 2017.

Bank Hapoalim BM reported no remaining AstraZeneca position as of Q4 2017 after selling out during the quarter.
Bank Hapoalim BM sold 14,658 AstraZeneca shares in Q4 2017, an estimated $993K.
Bank Hapoalim BM first reported a position in AstraZeneca in Q3 2016 and held it in 4 quarters.
Bank Hapoalim BM's AstraZeneca position peaked at $1.44M in Q2 2017.
503 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2017.

Based on Bank Hapoalim BM's 13F filing for Q4 2017, filed 5 Feb 2018.